ESSAY – PRECISION BIOTHERAPEUTICS
TITLE- Potential Use of CRISPR Technology in Precision Bio-Therapeutics for Treating Cancer.
[1] Dr. Arpita Mukherjee,
Ph.D., Department of Biochemistry
Independent Research Scientist (Biological Sciences), India
https://orcid.org/0009-0001-6038-7337.
E-mail- arpitamukherjee1987@rediffmail.com

In the last ten years, CRISPR has evolved from an acronym to a verb, revolutionizing biomedical research and opening up completely new avenues for analysing every aspect of cell biology. CRISPR and related technologies have opened a window into formerly unsolvable issues in our knowledge of cancer genetics, the noncoding genome, and tumor heterogeneity. They have also given rise to fresh perspectives on therapeutic vulnerabilities. In this article, we examine the advancements made in the use of CRISPR systems as a research tool for cancer and the new applications of these technologies to enhance cancer detection and therapy.
The field of cancer treatment has undergone a revolution with the discovery of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated protein 9 (Cas9) technologies. This essay delves into the application of CRISPR/Cas9 for editing and examines genes implicated in the development of human cancer. It sheds light on how CRISPR evolved into a genetic tool. It also looks at new advancements and resources for creating CRISPR/Cas9 systems that target cancer-causing genes. An overview of the biology of cancer, emphasizing important genomic changes and signaling pathways whose deletion stops cancer. Gaining an enhanced comprehension of how CRISPR/Cas9 can be customized to target particular genetic abnormalities and provide individualized treatment methods is made possible by this foundational knowledge. In this essay, the highlight of research and preclinical experiments that demonstrate the effectiveness of CRISPR/Cas9 in altering the tumor microenvironment, upregulating oncogenic targets, and boosting the effectiveness of currently existing anti-tumor therapies. It also sheds light on the application of CRISPR-based drug discovery screening as well as high throughput CRISPR screens for the identification of cancer biomarkers. Finally, this essay highlights the revolutionary potential of CRISPR for innovation and successful cancer treatments while providing an overview of the fascinating advances in building CRISPR/Cas9 medicines for cancer treatment.
By using the precision medicine method, each patient’s treatment can be tailored to the medications that are most likely to help, saving money and preventing negative side effects from medications that are unlikely to help. For instance, only 20% of patients with breast cancer who test positive for high levels of HER2 are eligible for medications that target the HER2 protein. The primary factor driving precision medicine in oncology at the moment is genomics. Precision medicine, however, may take into account additional variables, such as a patient’s illness presentation, gender, lifestyle, and exposure to substances like cigarette smoke that may cause cancer. Furthermore, future decisions about precision medicine are expected to be influenced by other aspects as research continues to provide light on both normal human biology and cancer biology.
The accuracy biotherapeutics are used across the full range of cancer care, from early detection and prevention of cancer to treating advanced stages of the illness.
More precision medicine applications in the treatment of other illnesses are to be expected; up until now, oncology has been at the forefront of these efforts, mostly due to our extensive understanding of the role that genetic abnormalities play in the onset and spread of cancer.

ESSAY – PRECISION BIOTHERAPEUTICS
TITLE- Potential Use of CRISPR Technology in Precision Bio-Therapeutics for Treating Cancer.
[1] Dr. Arpita Mukherjee,
Ph.D., Department of Biochemistry
Independent Research Scientist (Biological Sciences), India
https://orcid.org/0009-0001-6038-7337.
E-mail- arpitamukherjee1987@rediffmail.com

In the last ten years, CRISPR has evolved from an acronym to a verb, revolutionizing biomedical research and opening up completely new avenues for analysing every aspect of cell biology. CRISPR and related technologies have opened a window into formerly unsolvable issues in our knowledge of cancer genetics, the noncoding genome, and tumor heterogeneity. They have also given rise to fresh perspectives on therapeutic vulnerabilities. In this article, we examine the advancements made in the use of CRISPR systems as a research tool for cancer and the new applications of these technologies to enhance cancer detection and therapy.
The field of cancer treatment has undergone a revolution with the discovery of CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and CRISPR-associated protein 9 (Cas9) technologies. This essay delves into the application of CRISPR/Cas9 for editing and examines genes implicated in the development of human cancer. It sheds light on how CRISPR evolved into a genetic tool. It also looks at new advancements and resources for creating CRISPR/Cas9 systems that target cancer-causing genes. An overview of the biology of cancer, emphasizing important genomic changes and signaling pathways whose deletion stops cancer. Gaining an enhanced comprehension of how CRISPR/Cas9 can be customized to target particular genetic abnormalities and provide individualized treatment methods is made possible by this foundational knowledge. In this essay, the highlight of research and preclinical experiments that demonstrate the effectiveness of CRISPR/Cas9 in altering the tumor microenvironment, upregulating oncogenic targets, and boosting the effectiveness of currently existing anti-tumor therapies. It also sheds light on the application of CRISPR-based drug discovery screening as well as high throughput CRISPR screens for the identification of cancer biomarkers. Finally, this essay highlights the revolutionary potential of CRISPR for innovation and successful cancer treatments while providing an overview of the fascinating advances in building CRISPR/Cas9 medicines for cancer treatment.
By using the precision medicine method, each patient’s treatment can be tailored to the medications that are most likely to help, saving money and preventing negative side effects from medications that are unlikely to help. For instance, only 20% of patients with breast cancer who test positive for high levels of HER2 are eligible for medications that target the HER2 protein. The primary factor driving precision medicine in oncology at the moment is genomics. Precision medicine, however, may take into account additional variables, such as a patient’s illness presentation, gender, lifestyle, and exposure to substances like cigarette smoke that may cause cancer. Furthermore, future decisions about precision medicine are expected to be influenced by other aspects as research continues to provide light on both normal human biology and cancer biology.
The accuracy biotherapeutics are used across the full range of cancer care, from early detection and prevention of cancer to treating advanced stages of the illness.
More precision medicine applications in the treatment of other illnesses are to be expected; up until now, oncology has been at the forefront of these efforts, mostly due to our extensive understanding of the role that genetic abnormalities play in the onset and spread of cancer.

Dr Arpita Mukherjee

University/College name : Independent Research Scientist